| HAS [Haute Autorité de Santé – French National Authority for Health] contribution. | 風濕性
> 軸性脊椎關節炎 | 監管合作夥伴關係
> 與監管機構合作 | 1,000 | National | Sometimes | 114996619378 |
| Patient contribution to the HAS [Haute Autorité de Santé – French National Authority for Health]. | 癌症
> 癌症：血液 | 監管合作夥伴關係
> 與監管機構合作 | 100 | National | Sometimes | 114997550596 |
| Contributions during the evaluation of a new treatment. | 癌症
> 癌症：罕見 | 監管合作夥伴關係
> 與監管機構合作 | 1,000 | National | Rarely | 115021537282 |
| Submissions to the HAS [Haute Autorité de Santé – French National Authority for Health] and exchanges with the ANSM [Agence nationale de sécurité du médicament et des produits de santé – National Agency for the Safety of Medicines and Health Products]. | 罕見
> 罕見疾病：呼吸系統 | 監管合作夥伴關係
> 與監管機構合作 | 1,000 | National | Regularly | 115037393435 |
| Engagement with HAS [Haute Autorité de Santé – French National Authority for Health]. | 癌症
> 癌症：血液 | 監管合作夥伴關係
> 與監管機構合作 | 100,000 | National | Regularly | 115058165499 |
| ANSM [Agence nationale de sécurité du médicament et des produits de santé – National Agency for the Safety of Medicines and Health Products], the European Commission. | 罕見
> 罕見疾病：代謝/溶酶體 | 監管合作夥伴關係
> 與監管機構合作 | 5,000 | National | Sometimes | 119024758732 |
| Contributions submitted to the HAS [Haute Autorité de Santé – French National Authority for Health]. | 癌症
> 癌症：血液 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | 100,000 | National | Regularly | 114996624570 |
| ANSM [Agence nationale de sécurité du médicament et des produits de santé – National Agency for the Safety of Medicines and Health Products] sets the reimbursement rates for medicines. | 神經系統
> 神經系統：其他 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | 1,000 | National | Sometimes | 114996998287 |
| HAS [Haute Autorité de Santé – French National Authority for Health] consultations. | 罕見
> 罕見疾病：大多數類型 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | 1,000 | National | Sometimes | 114997498340 |
| ANSM [Agence nationale de sécurité du médicament et des produits de santé – National Agency for Medicines and Health Products Safety], HAS [Haute Autorité de Santé – French National Authority for Health]. | 神經退行性
> 柏金遜症 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | 100,000 | National | Sometimes | 115006691512 |
| HAS [Haute Autorité de Santé – French National Authority for Health] dossier submission for reimbursement. | 罕見
> 罕見疾病：遺傳性 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | 100 | National | Sometimes | 115007035544 |
| Our national organisation is frequently consulted by the HAS [Haute Autorité de Santé – French National Authority for Health] and the CEPS [Comité Économique des Produits de Santé – Economic Committee for Health Products]. At the regional level, we contribute through concrete examples. | 罕見
> 罕見疾病：大多數類型 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | 1,000 | Regional | Rarely | 115019695255 |
| HAS [Haute Autorité de Santé – French National Authority for Health]. | 癌症
> 癌症：肺 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | 100 | National | Sometimes | 115023193878 |
| HAS [Haute Autorité de Santé – French National Authority for Health]. | 風濕性
> 風濕病：大多數類型 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | 100,000 | National | Regularly | 115028340764 |
| Submissions to the HAS [Haute Autorité de Santé – French National Authority for Health] and exchanges with the ANSM [Agence nationale de sécurité du médicament et des produits de santé – National Agency for the Safety of Medicines and Health Products]. | 罕見
> 罕見疾病：呼吸系統 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | 1,000 | National | Regularly | 115037393435 |
| HAS [Haute Autorité de Santé – French National Authority for Health], ANSM [Agence nationale de sécurité du médicament et des produits de santé – National Agency for the Safety of Medicines and Health Products], DGOS [Direction générale de l'offre de soins – Directorate General for Health Care Provision]. | 罕見
> 罕見疾病：貧血症 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | 1,000 | National | Regularly | 115051867960 |
| Engagement with HAS [Haute Autorité de Santé – French National Authority for Health]. | 癌症
> 癌症：血液 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | 100,000 | National | Regularly | 115058165499 |
| HAS [Haute Autorité de Santé – French National Authority for Health], contributions to the AMM [autorisation de mise sur le marché – marketing authorisation] processes for new medicines. | 出血
> 出血性疾病：其他 | 監管合作夥伴關係
> 為市場授權申請作出貢獻 | 1,000 | National | Regularly | 114998547552 |
| Opinions on new medicines prior to AMM [Autorisation de Mise sur le Marché – Marketing Authorisation]. | 病人安全
> 醫源性 | 監管合作夥伴關係
> 為市場授權申請作出貢獻 | 1,000 | National | Regularly | 115006692431 |
| HAS [Haute Autorité de Santé – French National Authority for Health] contributions in support of AMM [Autorisation de Mise sur le Marché – Marketing Authorisation] applications. | 神經肌肉
> 重症肌無力 | 監管合作夥伴關係
> 為市場授權申請作出貢獻 | Do not know | International | Regularly | 115019651354 |
| Apprenticeship programme at the ANSM [Agence nationale de sécurité du médicament et des produits de santé – National Agency for the Safety of Medicines and Health Products], contributing to the evaluation of medicinal products. | 內分泌
> 生長障礙 | 監管合作夥伴關係
> 為市場授權申請作出貢獻 | 1,000 | International | Regularly | 115043122988 |
| Participation in fast-track designations for clinical trials, inclusion of adolescents, the Biotech Act, and related initiatives. | 癌症
> 癌症：兒童／青少年 | 監管合作夥伴關係
> 為市場授權申請作出貢獻 | 1,000 | International | Regularly | 115053274069 |
| ANSM [Agence nationale de sécurité du médicament et des produits de santé – National Agency for the Safety of Medicines and Health Products]. | 心血管
> 心血管：大多數類型 | 監管合作夥伴關係
> 為市場授權申請作出貢獻 | 1,000 | National | Regularly | 115057828483 |
| Our national organisation is frequently consulted by the HAS [Haute Autorité de Santé – French National Authority for Health] and the CEPS [Comité Économique des Produits de Santé – Economic Committee for Health Products]. At the regional level, we contribute through concrete examples. | 罕見
> 罕見疾病：大多數類型 | 監管合作夥伴關係
> 出席/主持與政策制定者/監管機構的會議 | 1,000 | Regional | Rarely | 115019695255 |
| Consultation with the Ministry of Health. | 癌症
> 癌症：乳腺癌 | 監管合作夥伴關係
> 出席/主持與政策制定者/監管機構的會議 | 10,000 | National | Rarely | 115037385316 |
| Apprenticeship programme at the ANSM [Agence nationale de sécurité du médicament et des produits de santé – National Agency for the Safety of Medicines and Health Products], contributing to the evaluation of medicinal products. | 內分泌
> 生長障礙 | 監管合作夥伴關係
> 出席/主持與政策制定者/監管機構的會議 | 1,000 | International | Regularly | 115043122988 |
| Engagement with members of parliament, the Ministry of Health, and the HAS [Haute Autorité de Santé – French National Authority for Health]; advocacy efforts to remove genomic tests from the RIHN [Référentiel des actes Innovants Hors Nomenclature – Reference Framework for Innovative Acts Outside the Nomenclature]; presentations at congresses and seminars; and chairing of symposia. | 癌症
> 癌症：乳腺癌 | 監管合作夥伴關係
> 出席/主持與政策制定者/監管機構的會議 | 10,000 | National | Regularly | 115049335124 |
| Participation in fast-track designations for clinical trials, inclusion of adolescents, the Biotech Act [at EU level], and related initiatives. | 癌症
> 癌症：兒童／青少年 | 影響政策及立法
> 影響醫療保健政策及立法 | 1,000 | International | Regularly | 115053274069 |
| Engagement with members of parliament, the Ministry of Health, and the HAS [Haute Autorité de Santé – French National Authority for Health]; advocacy efforts to remove genomic tests from the RIHN [Référentiel des actes Innovants Hors Nomenclature – Reference Framework for Innovative Acts Outside the Nomenclature]; presentations at congresses and seminars; and chairing of symposia. | 癌症
> 癌症：乳腺癌 | 影響政策及立法
> 動員議員及政治領袖 | 10,000 | National | Regularly | 115049335124 |
| Regarding the reimbursement of growth hormone in 2012. | 罕見
> 罕見疾病：遺傳性 | 定價及可負擔性倡議
> 倡導公平藥品定價 | 100 | National | Sometimes | 114999124203 |
| Legislation on patient out-of-pocket costs. | 癌症
> 癌症：乳腺癌 | 定價及可負擔性倡議
> 倡導公平藥品定價 | 1,000 | National | Regularly | 115028639358 |
| ANSM [Agence nationale de sécurité du médicament et des produits de santé – National Agency for the Safety of Medicines and Health Products] sets the reimbursement rates for medicines. | 神經系統
> 神經系統：其他 | 定價及可負擔性倡議
> 參與價格審查委員會談判 | 1,000 | National | Sometimes | 114996998287 |
| Legislation on patient out-of-pocket costs. | 癌症
> 癌症：乳腺癌 | 定價及可負擔性倡議
> 解決低收入及弱勢群體的費用負擔問題 | 1,000 | National | Regularly | 115028639358 |
| Reimbursement of growth hormone. | 一般健康
> 一般健康 | 定價及可負擔性倡議
> 倡導將產品納入報銷清單／國家藥品目錄 | 100 | National | Sometimes | 114996944911 |
| Regarding the reimbursement of growth hormone in 2012. | 罕見
> 罕見疾病：遺傳性 | 定價及可負擔性倡議
> 倡導將產品納入報銷清單／國家藥品目錄 | 100 | National | Sometimes | 114999124203 |
| Advocacy efforts to remove genomic tests from the RIHN [Référentiel des actes Innovants Hors Nomenclature – Reference Framework for Innovative Acts Outside the Nomenclature] [The issue centers on genomic signature tests used in early-stage hormone receptor–positive, HER2-negative breast cancer, to determine whether adjuvant chemotherapy is likely to provide meaningful benefit. The logic is that this should allow many women to avoid unnecessary chemotherapy. However, the French breast-cancer patient groups argue that under the RIHN scheme elligible patients find it difficult to access the genomic tests. They want the genomic tests to be made available through the general social-security system.] | 癌症
> 癌症：乳腺癌 | 定價及可負擔性倡議
> 倡導將產品納入報銷清單／國家藥品目錄 | 10,000 | National | Regularly | 115049335124 |
| Correspondence submitted to request reimbursement of a specific voice prosthesis. | 殘疾
> 殘疾：其他 | 改善存取途徑
> 促進公平獲取藥物／醫療保健 | 1,000 | National | Rarely | 115012114375 |
| Hybrid closed-loop systems, new CGM [Continuous Glucose Monitoring] devices. | 內分泌
> 糖尿病（1型及2型） | 改善存取途徑
> 促進公平獲取藥物／醫療保健 | 100 | Regional | Regularly | 115028487590 |
| The HAS [Haute Autorité de Santé – French National Authority for Health] should facilitate access to innovative medicines that hold a temporary authorisation. | 癌症
> 癌症：血液 | 改善存取途徑
> 促進公平獲取藥物／醫療保健 | 1,000 | National | Regularly | 115051136978 |
| Patient advisory council for scientific studies. | 一般健康
> 肥胖症 | 以實證為基礎的患者意見
> 利用患者洞察來輔助決策 | 1,000 | International | Regularly | 115028400081 |
| Patient contributions to the HAS [Haute Autorité de Santé – French National Authority for Health]. | 癌症
> 癌症：血液 | 以實證為基礎的患者意見
> 善用患者故事及親身經歷敘述 | 100 | National | Sometimes | 114997550596 |
| Our national organisation is frequently consulted by the HAS [Haute Autorité de Santé – French National Authority for Health] and the CEPS [Comité Économique des Produits de Santé – Economic Committee for Health Products]. At the regional level, we contribute through concrete examples. | 罕見
> 罕見疾病：大多數類型 | 以實證為基礎的患者意見
> 善用患者故事及親身經歷敘述 | 1,000 | Regional | Rarely | 115019695255 |
| Clinical trials, opinion videos. | 內分泌
> 糖尿病（1型及2型） | 以實證為基礎的患者意見
> 善用患者故事及親身經歷敘述 | 100,000 | National | Sometimes | 115049743006 |
| Patient rights and contributing our experience as patients. | 心血管
> 心血管：大多數類型 | 以實證為基礎的患者意見
> 善用患者故事及親身經歷敘述 | 100 | Regional | Regularly | 115060504774 |
| Questionnaire for input from patient and user associations. | 心血管
> 家族性高膽固醇血症（FH） | 以實證為基礎的患者意見
> 進行調查/研究以產生數據 | 1,000 | National | Sometimes | 115053041303 |
| Patient advisory council for scientific studies. | 一般健康
> 肥胖症 | 診斷及藥物送遞
> 協作設計臨床試驗 | 1,000 | International | Regularly | 115028400081 |
| Clinical trials. | 內分泌
> 糖尿病（1型及2型） | 診斷及藥物送遞
> 協作設計臨床試驗 | 100,000 | National | Sometimes | 115049743006 |
| Participation in fast-track designations for clinical trials, inclusion of adolescents, the Biotech Act, and related initiatives. | 癌症
> 癌症：兒童／青少年 | 診斷及藥物送遞
> 協作設計臨床試驗 | 1,000 | International | Regularly | 115053274069 |
| The Fédération Française des Groupements de Parkinsoniens [French Federation of Parkinson's Patient Groups] represents Parkinson's patients in health governance bodies and ministerial forums. | 神經退行性
> 柏金遜症 | 機構管治
> 確保在政府諮詢機構中獲得代表席位 | 1,000 | National | Regularly | 114997021296 |
| ANRS [Agence nationale de recherches sur le sida et les hépatites virales – National Agency for Research on AIDS and Viral Hepatitis], Coress [Coordination régionale en santé sexuelle - Regional Coordination for Sexual Health]. | HIV
> HIV及肝炎 | 機構管治
> 在多方持份者網絡中有效運作 | 1,000 | National | Regularly | 115035724756 |
| Advocacy, discrimination. | 風濕性
> 銀屑病及銀屑病關節炎 | 維護病人權益／提升生活質素
> 保護/改善患者體驗 | 100,000 | National | Regularly | 115042996062 |
| Patient rights and contributing our experience as patients. | 心血管
> 心血管：大多數類型 | 維護病人權益／提升生活質素
> 保護/改善患者體驗 | 100 | Regional | Regularly | 115060504774 |
互動
行動與倡議
27 提及
